+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07089641

Evaluating ERAS-801 Oral Treatment for Adults with Resectable EGFR-Positive Grade IV Glioblastoma or Gliosarcoma in a Phase Ib Trial

Led by Jonsson Comprehensive Cancer Center · Updated on 2026-09-18

50

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ERAS-801, an EGFR inhibitor, in adults with resectable, progressive, recurrent, or newly diagnosed elderly glioblastoma or gliosarcoma tumors that have EGFR amplification or mutation but are IDH wildtype. This phase Ib trial aims to assess the safety, tolerability, pharmacokinetics, and effects of ERAS-801 on tumor glucose utilization, tumor response, and six-month progression-free survival. The study includes several specific patient groups based on disease status and age, addressing a brain cancer with poor survival rates despite current treatments. Participants are assigned to one of three cohorts depending on their disease status Cohort A receives ERAS-801 once daily orally for 8-14 days before scheduled surgery, followed by cycles of treatment every 28 days post-surgery Cohort B includes patients with recurrent glioblastoma treated twice daily in 28-day cycles Cohort C enrolls newly diagnosed elderly patients treated twice daily in similar cycles starting within weeks of surgery. Throughout the study, patients undergo brain MRI, FDG PET scans, echocardiography, urine and blood sample collection, and cerebrospinal fluid sampling at surgery. During the trial, participants are monitored for tumor activity using imaging and biomarker tests before, during, and after treatment cycles. Safety and side effects are tracked, along with pharmacokinetics and pharmacodynamics of ERAS-801. After treatment, patients have follow-up visits starting 30 days later, then every two months until disease progression or study end, and less frequent visits if progression occurs. The study measures outcomes such as tumor glucose use, drug concentration effects, and six-month progression-free survival over the course of participation.

CONDITIONS

Brief Title

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here